Printer Friendly

NEOVACS AND STELLAR SIGN JOINT VENTURE AGREEMENT.

Neovacs has finalized the terms of its partnership with US company Stellar Biotechnologies Inc. ("Stellar") (Nasdaq: SBOT), to determine the creation of the production company Neostell SAS under a form of a joint venture, based in the Paris area and owned 70% by Neovacs and 30% by Stellar Biotechnologies.

Under the terms of this joint venture agreement, Neovacs and Stellar Biotechnologies have agreed to combine their skills, to manufacture and sell all types of conjugated vaccines to third party customers worldwide, as well as produce all of Neovacs' Kinoids, including IFNa-Kinoid. Investments for this production unit will start after the results of the Phase IIb study of IFNa-Kinoid in lupus conducted by Neovacs and currently ongoing. Beyond the interest of 30 % held by Stellar Biotechnologies, Neovacs has received 5 million for this project from the public funding program PIAVE set up by Bpifrance.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is a sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH- based active immunotherapies.

About Neovacs

Created in 1993, Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information, visit www.neovacs.fr or call 646/536-7006.

COPYRIGHT 2016 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Jun 1, 2016
Words:366
Previous Article:CYNATA ENTERS LICENSE OPTION AGREEMENT WITH APCETH.
Next Article:OREXO SIGNS LICENSE AGREEMENT WITH MUNDIPHARMA.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters